Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).

Sham Mailankody, Sandy W. Wong, Siddhartha Ganguly et al.|Journal of Clinical Oncology|2020

Cited by 122